| pubmed-article:7721437 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C1134681 | lld:lifeskim |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:7721437 | lifeskim:mentions | umls-concept:C0255372 | lld:lifeskim |
| pubmed-article:7721437 | pubmed:issue | 4 Pt 2 | lld:pubmed |
| pubmed-article:7721437 | pubmed:dateCreated | 1995-5-25 | lld:pubmed |
| pubmed-article:7721437 | pubmed:abstractText | Indirect evidence has implicated endothelin-1 in the pathogenesis of hypertension. In the present study we examined such a role directly with SB 209670, a novel nonpeptide endothelin receptor antagonist. The antihypertensive and hemodynamic effects of SB 209670 were examined in conscious, unrestrained spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY), and renin-hypertensive rats. Sustained intravenous infusion of SB 209670 (10 micrograms.kg-1.min-1 for 6 hours) produced a significant, reversible reduction in mean arterial pressure in SHR but not in WKY rats. The antihypertensive response to 10 micrograms.kg-1.min-1 SB 209670 (approximately 25 mm Hg reduction in blood pressure) was associated with bradycardia (16% decrease in heart rate) but only a minimal reduction (3%) in cardiac output, because stroke volume was evaluated (by 15%). Therefore, the antihypertensive effect of SB 209670 resulted from a decrease (13%) in total peripheral resistance. A sustained antihypertensive effect could also be observed after intraduodenal administration of SB 209670 (3 mg/kg) in conscious SHR (reduction of approximately 35 mm Hg 5 hours after administration). SB 209670 (3 mg/kg intravenous bolus) did not alter the pressor response or tachycardia observed in pithed SHR after stimulation of thoracolumbar sympathetic outflow. SB 209670 was also antihypertensive in renin-hypertensive rats, lowering blood pressure to an extent similar to that observed in SHR. Thus, the data presented provide evidence to support a role for endothelin-1 in the pathophysiology of two animal models of hypertension. | lld:pubmed |
| pubmed-article:7721437 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7721437 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7721437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7721437 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7721437 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:7721437 | pubmed:issn | 0194-911X | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:OhlsteinE HEH | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:GellaiMM | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:EzekielMM | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:ElliottJ DJD | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:FeuersteinG... | lld:pubmed |
| pubmed-article:7721437 | pubmed:author | pubmed-author:DouglasS ASA | lld:pubmed |
| pubmed-article:7721437 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7721437 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:7721437 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7721437 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7721437 | pubmed:pagination | 818-22 | lld:pubmed |
| pubmed-article:7721437 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:meshHeading | pubmed-meshheading:7721437-... | lld:pubmed |
| pubmed-article:7721437 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7721437 | pubmed:articleTitle | Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. | lld:pubmed |
| pubmed-article:7721437 | pubmed:affiliation | Department of Cardiovascular Pharmacology (UW 2510), SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA. | lld:pubmed |
| pubmed-article:7721437 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7721437 | lld:pubmed |
